| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEA5 |
| Uniprot No | P43359 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-124aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHGASAIPTAID FTLWRQSIKG SSNQEEEGPS TSPDPESVFR AALSKKVADL IHFLLLKYMSLEQK SQHCKPEEGL DTQEEALGLV GVQAATTEEQ EAVSSSSPLV PGTLGEVPAA GSPGPLKSPQ |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
**Background of MAGEA5 Recombinant Protein**
The MAGE family member A5 (MAGEA5), part of the melanoma-associated antigen (MAGE) gene family, is a cancer-testis antigen (CTA) predominantly expressed in germline cells (e.g., testes, placenta) and silenced in most healthy somatic tissues. However, MAGEA5 is aberrantly reactivated in various cancers, including melanoma, lung, breast, and hepatocellular carcinomas, making it a potential biomarker and therapeutic target.
Structurally, MAGEA5 encodes a protein with a conserved MAGE homology domain, which facilitates protein-protein interactions, particularly with E3 ubiquitin ligases. This interaction modulates ubiquitination pathways, influencing cell cycle regulation, apoptosis, and epigenetic modifications. MAGEA5 overexpression in tumors is linked to oncogenic roles, such as promoting proliferation, metastasis, and resistance to therapy, potentially via dysregulation of p53 or Wnt/β-catenin signaling.
Recombinant MAGEA5 protein is engineered using heterologous expression systems (e.g., *E. coli*, mammalian cells) to produce purified, biologically active forms for research and clinical applications. It serves as a critical tool for studying MAGEA5's molecular mechanisms, antibody development, and T-cell-based immunotherapies. In cancer vaccines or adoptive cell therapies (e.g., CAR-T), recombinant MAGEA5 aids in eliciting targeted immune responses against MAGEA5-expressing tumors.
Despite its promise, challenges remain, including MAGEA5's low immunogenicity and potential off-target effects due to its restricted but non-zero expression in some healthy tissues. Ongoing research aims to optimize MAGEA5-targeted strategies while minimizing toxicity, underscoring its dual role as a therapeutic opportunity and a biological puzzle in cancer immunology.
×
